Excluding revenues and costs from the previously announced exited reproductive health and somatic tumor testing businesses, management expects GeneDx to: Generate pro forma revenues between $170-173 million in 2022, an approximate 37-40% increase from pro forma $123.7 million in 2021; Produce pro forma test result volume of more than 180,000 in 2022, an approximate 23% increase from pro forma test result volume of 147,000 in 2021; and Deliver pro forma adjusted gross margin between 38-41% in 2022, up from 34% in 20211. "We are pleased by the acceleration of our business throughout 2022, especially the fourth quarter which set a new all-time high for test result volume. Our preliminary results, which exceeded our outlook a year ago, validate our strategy to target higher growth areas of the genomics market," said Kevin Feeley, Chief Financial Officer of GeneDx.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on SMFR:
- Sema4|GeneDx to Participate in the 41st Annual J.P. Morgan Healthcare Conference
- Myriad Genetics appoints Glenn Farrell as CMO
- Sema4 Holdings downgraded to Neutral from Buy at Goldman Sachs
- Sema4 announces results of new study on mitochondrial diseases in newborns
- New Research from Sema4|GeneDx Highlights the Importance of Rapid Exome Sequencing for Diagnosing Mitochondrial Diseases in the NICU
